Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAZTIA XT vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Hypertension (FDA-approved),Chronic stable angina (FDA-approved),Variant angina (FDA-approved),Atrial fibrillation or atrial flutter (rate control, off-label),Supraventricular tachycardia (off-label)
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
3-5 hours (immediate-release) for diltiazem; after TAZTIA XT extended-release, effective half-life is approximately 7-9 hours due to prolonged absorption. Clinical context: steady state achieved in 3-5 days.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Hepatic via CYP3A4; active metabolite (desacetyldiltiazem).
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal (approximately 60% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion), biliary/fecal (approximately 30-35%)
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
70-80% primarily to albumin; also to alpha-1-acid glycoprotein
Approximately 90% bound to plasma proteins, primarily albumin.
3.1-5.3 L/kg (central compartment); large Vd indicates extensive tissue distribution, consistent with high lipophilicity and cardiac/vascular tissue binding.
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral (extended-release): approximately 35-60% due to extensive first-pass hepatic metabolism (cytochrome P450 3A4) with significant interindividual variability. Food may increase bioavailability by up to 20%.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No specific dose adjustment recommended for mild to moderate renal impairment. Use caution in severe renal impairment (Cr Cl <30 m L/min); consider starting at lower dose and titrate slowly.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh Class A or B: No specific adjustment, but use caution. Child-Pugh Class C: Contraindicated.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Safety and efficacy not established; no pediatric dosing guidelines available.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Start at lower end of dosing range (120 mg once daily) due to increased systemic exposure; titrate slowly based on response and tolerability.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
No FDA boxed warning specific to TAZTIA XT; however, the drug class (calcium channel blockers) may have warnings for increased risk of cardiovascular events in certain populations.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Heart failure: May worsen symptoms due to negative inotropic effects.,Bradycardia and heart block: Risk especially in elderly or with other AV nodal blockers.,Hypotension: Especially with rapid dose escalation.,Abrupt withdrawal: May cause rebound angina or hypertension.,Hepatic impairment: Reduced metabolism may require dose adjustment.,Concomitant use with beta-blockers: Increased risk of bradycardia and heart block.
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Hypotension (systolic <90 mm Hg),Acute myocardial infarction or pulmonary congestion,Known hypersensitivity to diltiazem,Concurrent use with ivabradine
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase diltiazem plasma concentrations, elevating risk of bradycardia and hypotension. No other significant food interactions. Administer with or without food.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
TAZTIA XT (diltiazem) is classified as FDA Pregnancy Category C. In first trimester, animal studies have shown embryofetal toxicity (skeletal abnormalities, fetal mortality) at doses ≥5 times maximum human dose. No adequate human studies in pregnant women; potential risk cannot be ruled out. In second and third trimesters, use may cause uteroplacental hypoperfusion due to maternal hypotension, potentially leading to fetal hypoxia and growth restriction. Case reports associate with preterm labor and low birth weight. Avoid use during pregnancy unless benefit outweighs risk.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Diltiazem is excreted into breast milk at low concentrations. A study reported milk-to-plasma (M/P) ratio of approximately 0.8-1.0. Estimated infant dose is <1% of maternal weight-adjusted dose, considered clinically insignificant. However, due to potential for adverse effects (hypotension, bradycardia) in neonates, caution advised. American Academy of Pediatrics considers diltiazem compatible with breastfeeding. Monitor infant for signs of bradycardia or hypotension.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No standard dosing adjustments established for pregnancy. However, pregnancy-induced physiological changes (increased plasma volume, renal clearance, and hepatic metabolism) may reduce diltiazem plasma concentrations. Monitor therapeutic effect and consider dose titration based on blood pressure response and heart rate. Limited data suggest that higher doses may be required. Adjust dose cautiously to avoid maternal hypotension, which could compromise uteroplacental perfusion.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
TAZTIA XT is a once-daily extended-release formulation of diltiazem (240 mg, 300 mg, 360 mg). Use for hypertension or chronic stable angina. Doses >360 mg are not recommended. Do not crush or chew; the matrix delivery system can cause bezoars. Avoid use in sick sinus syndrome without a pacemaker, second- or third-degree AV block, or hypotension (SBP <90 mm Hg). Monitor for bradycardia and peripheral edema. Abrupt withdrawal may exacerbate angina. Contraindicated with IV beta-blockers or in patients with atrial fibrillation/flutter with accessory bypass tract (e.g., WPW).
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take TAZTIA XT once daily at approximately the same time every day, with or without food.,Swallow the capsule whole; do not crush, chew, or open it. The empty shell may appear in stool.,Avoid grapefruit and grapefruit juice as it can increase diltiazem levels and risk of side effects.,Do not suddenly stop taking this medication without consulting your doctor, as chest pain or heart attack may worsen.,Report symptoms like slow heartbeat, dizziness, fainting, or swelling of the ankles/feet.,Limit alcohol intake as it can increase dizziness and lower blood pressure.,Warn about interactions with beta-blockers, digoxin, statins, and CYP3A4 inhibitors/inducers.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAZTIA XT vs CALAN, answered by our medical review team.
TAZTIA XT is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary arteries and peripheral arterioles, and reduction of myocardial contractility and heart rate.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAZTIA XT and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAZTIA XT is: Oral, 120 mg or 180 mg once daily. For hypertension, initiate at 120 mg once daily; for angina, initiate at 180 mg once daily. Maximum dose: 360 mg once daily.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAZTIA XT and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAZTIA XT is classified as Category C. TAZTIA XT (diltiazem) is classified as FDA Pregnancy Category C. In first trimester, animal studies have shown embryofetal toxicity (skeletal abnormalities, fetal mortality) at dos. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.